Free Trial
Invest Smarter with A.I. PowerGet 30 Days Free

Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Crosses Above 50 Day Moving Average - Time to Sell?

Written by MarketBeat
October 11, 2025
Northwest Biotherapeutics logo with Medical background

Key Points

  • Northwest Biotherapeutics shares have surpassed their 50-day moving average of $0.25, trading as high as $0.26 on Friday with a volume of over 3 million shares.
  • The company reported a quarterly earnings loss of ($0.01) EPS and revenue of $0.13 million, highlighting ongoing financial challenges.
  • Northwest Biotherapeutics develops personalized immune therapies for cancer using its DCVax platform, which mobilizes the patient's immune system against tumors.
  • Interested in Northwest Biotherapeutics? Here are five stocks we like better.

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) shares passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.25 and traded as high as $0.26. Northwest Biotherapeutics shares last traded at $0.25, with a volume of 3,156,431 shares trading hands.

Northwest Biotherapeutics Stock Performance

The business's 50-day moving average price is $0.25 and its 200 day moving average price is $0.26. The company has a market cap of $378.69 million, a P/E ratio of -4.15 and a beta of -0.70.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The biotechnology company reported ($0.01) EPS for the quarter. The firm had revenue of $0.13 million for the quarter.

About Northwest Biotherapeutics

(Get Free Report)

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Northwest Biotherapeutics Right Now?

Before you consider Northwest Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.

While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.